Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.